Skip to main content

Advanced Search

Advanced Search

Current Filters

Filter your query

Publication Types



Panos Kanavos

2001-02 Harkness Fellow Lecturer in international health policy and Director of the master of science in international health policy program Department of Social Policy and Administration London School of Economics and Political Science

Harkness Project Title:  Uptake and Utilization of Statins in the United States: Evidence from Medical Expenditure Panel Survey

Mentor: Steve Soumerai, Sc.D.

Placement: Harvard Medical School/Harvard Pilgrim Health Care

Biography at time of Harkness Fellowship: Panos Kanavos, a 2001–02 Commonwealth Fund Harkness Fellow in Health Care Policy, is a lecturer in international health policy and director of the master of science in international health policy program in the Department of Social Policy and Administration at the London School of Economics and Political Science. His research interests include the financing of health services, pharmaceutical policy, the economics of health-related high technology (pharmaceuticals, biotechnology, and medical devices), and the health problems of economies in transition. He has published widely on health care reform issues, pharmaceutical economics, and policy. Kanavos served as advisor on health care reform and pharmaceutical policy in a variety of Eastern European countries and the Philippines and is a former alternate member of the executive committee of the National Drug Organization of Greece. He has also served as temporary advisor to and has received research grants from the World Health Organization, World Bank, Organization for Economic Cooperation and Development, European Commission, and European Parliament.


Project: Panos Kanavos explored the predictors of statin use in the U.S. between 1996 and 1998 for both primary and secondary prevention.  He also explored how statin use during this period compared with published evidence on good clinical practice.  He used data from the Medical Expenditure Panel Survey (MEPS) to identify patients who, on the basis of published clinical evidence, would qualify to receive a statin.  He also conducted a retrospective multivariate logistic analysis on predictors of statin use, including socioeconomic and clinical factors.

Career Activity Since Fellowship


  • Program Director of the Medical Technology Research Group at LSE Health, 2009
  • Reader in International Health Policy, Department of Social Policy, London School of Economics, 2006
  • Merck Fellow in Pharmaceutical Policy, LSE Health, 2006
  • Research Fellow in Pharmaceutical Economics, LSE Health and Social Care, London School of Economics and Political Science, 2003

Current Position: Director, International Health Policy Programme (Health Economics), LSE Health, and Senior Lecturer and Head, Medical Technology Research Unit, Department of Social Policy, London School of Economics. (1/2014)

E-Mail: [email protected]

Selected Publications



Grimaccia F, Kanavos P. Cost, outcomes, treatment pathways and challenges for diabetes care in Italy. Global Health. 2014 Jul 14;10:58. 

Tordrup D, Mossman J, Kanavos P. Responsiveness of the EQ-5D to clinical change: is the patient experience adequately represented? Int J Technol Assess Health Care. 2014 Jan;30(1):10-19. 

Bertoldi AD, Kanavos P, França GV, Carraro A, Tejada CA, Hallal PC, Ferrario A, Schmidt MI. Epidemiology, management, complications and costs associated with  type 2 diabetes in Brazil: a comprehensive literature review. Global Health. 2013 Dec 3;9:62.

Tordrup D, Angelis A, Kanavos P. Preferences on policy options for ensuring the financial sustainability of health care services in the future: results of a  stakeholder survey. Appl Health Econ Health Policy. 2013 Dec;11(6):639-52.




Kanavos P, Ferrario A, Vandoros S, Anderson GF. “Higher US Branded Drug Prices And Spending Compared To Other Countries May Stem Partly From Quick Uptake Of New Drugs” Health Affairs 2013; 32(4):753-61.




Kanavos P, Nicod E. “Commonalities and differences in HTA outcomes: A comparative analysis of five countries and implications for coverage decisions.” Health Policy, October 2012.




Kanavos P, Nicod E. What is wrong with orphan drug policies? Suggestions for ways forward. Value Health. 2012 Dec;15(8):1182-4.




Yang W, Kanavos P. The less healthy urban population: income-related health inequality in China. BMC Public Health. 2012 Sep 18;12:804.




Kanavos PG, Vandoros S. Determinants of branded prescription medicine prices in OECD countries. Health Econ Policy Law. 2011 Jul;6(3):337-67.




von der Schulenburg F, Vandoros S, Kanavos P. The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors. Health Econ Rev. 2011 Nov 21;1(1):18.




Sorenson C, Kanavos P. Medical technology procurement in Europe: a cross-country comparison of current practice and policy. Health Policy. 2011Apr;100(1):43-50.




Kanavos P, Gemmill-Toyama M. Prescription drug coverage among elderly and disabled Americans: can Medicare-Part D reduce inequities in access? Int J Health Care Finance Econ. 2010 Sep;10(3):203-18.




Lluch M, Kanavos P. Impact of regulation of Community Pharmacies on efficiency, access and equity. Evidence from the UK and Spain. Health Policy. 2010 May;95(2-3):245-54.




Kanavos P, Vandoros S, Garcia-Gonzalez P. Benefits of global partnerships to  facilitate access to medicines in developing countries: a multi-country analysis  of patients and patient outcomes in GIPAP. Global Health. 2009 Dec 31;5:19.




Kanavos P, Sullivan R, Lewison G, Schurer W, Eckhouse S, Vlachopioti Z. The role of funding and policies on innovation in cancer drug development. Ecancermedicalscience. 2010;4:164.




Kanavos P, Schurer W. The burden of colorectal cancer: prevention, treatment  and quality of services. Eur J Health Econ. 2010 Jan;10 Suppl 1:S1-3.




Kanavos P, Schurer W. The dynamics of colorectal cancer management in 17 countries. Eur J Health Econ. 2010 Jan;10 Suppl 1:S115-29.




Schurer W, Kanavos P. Colorectal cancer management in the United Kingdom: current practice and challenges. Eur J Health Econ. 2010 Jan;10 Suppl 1:S85-90.




Kanavos P, Taylor D. Pharmacy discounts on generic medicines in France: is there room for further efficiency savings? Curr Med Res Opin. 2007 Oct;23(10):2467-76.




Kanavos P. Do generics offer significant savings to the UK National Health Service? Curr Med Res Opin. 2007 Jan;23(1):105-16.

 Panos Kanavos, Joan Costa Font, Alistair McGuire. "Product differentiation, competition and regulation of new drugs: the case of statins in four European countries," Managerial and Decision Economics. Chichester: Jun-Aug 2007. Vol. 28, Iss. 4/5; pg. 455

Morgan SG, McMahon M, Mitton C, Roughead E, Kirk R, Kanavos P, Menon D. “Centralized Drug Review Processes in Australia, Canada, New Zealand, and the United Kingdom,” Health Affairs 2006; 25(2):337-347

Kanavos P, Gemmill M., “Senior citizens and the burden of prescription drug outlays : what lessons for the medicare prescription drug benefit?” Appl Health Econ Health Policy. 2004;3(4):217-27

Reinhardt U, Kanavos P. “Reference Pricing for Drugs: Is it Compatible With U.S. Health Care?” Health Affairs 2003; 22(3):16-28. 

Pollack M, Kanavos P, Link C. Variations in Prescribing Patterns of Atypical Antipsychotics: A Probit Analysis of the NAMCS and NHAMCS Surveys for the Period 1992 – 1999. Department of Economics, University of Delaware, May 2002.